Loading...
Janus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literature
Morrissey, Hana Askari, Ayman NOURI, ABDULLA KHALID
Morrissey, Hana
Askari, Ayman
NOURI, ABDULLA KHALID
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2019-11-15
Submitted date
Alternative
Abstract
Cytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors promises the start of a revolution in the treatment of several chronic diseases. Their efficacy and safety profile have been demonstrated in multiple trials and they have been licensed for the treatment of a number of diseases including RA and PsA. Moreover, the use of highly selective Janus Kinase Enzyme inhibitors is currently being studied aiming to reduce side effects compared with traditional JAKinibs, an example of that would be the recent FDA approved upadacitinib. The Janus Kinase Enzyme inhibitorsmay supplant the classical biologic agents in the treatment of autoimmune diseases, since they exhibitthe advantages of oral administration, simultaneous blockade of multiple cytokines, reversibility and the lack of immunogenicity.
Citation
Askari, A., Nouri, A. K., Morrissey, H. and Ball, P. A. (2019) Janus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literature, International Journal of Current Pharmaceutical Research, 11(6), pp. 11-14, doi:10.22159/ijcpr.2019v11i6.36343.
Publisher
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Type
Journal article
Language
en
Description
Series/Report no.
ISSN
0975-7066